Stocktoria
Jaguar Health, Inc. JAGX
Jaguar Health, Inc. (JAGX) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $11.5M at a -465.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| JAGX | Jaguar Health, Inc. | 2/9 | — | — | -1.5% |
| PRLD | Prelude Therapeutics Inc | 3/9 | -17.29 | — | — |
| CBIO | CRESCENT BIOPHARMA, INC. | 4/9 | 4.59 | — | — |
| EVMN | Evommune, Inc. | 2/9 | 9.47 | — | — |
| JANX | Janux Therapeutics, Inc. | 2/9 | — | — | -5.6% |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 3/9 | -0.37 | — | +29.8% |
| PRTA | PROTHENA CORP PUBLIC LTD CO | 1/9 | -5.98 | — | -92.8% |
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
FAQ
Is JAGX financially healthy?
Jaguar Health, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does JAGX pay a dividend?
No, Jaguar Health, Inc. does not currently pay a dividend.
How profitable is JAGX?
In FY2025, Jaguar Health, Inc. had a net margin of -465.4%.
What is the analyst price target for JAGX?
The average Wall-Street price target for Jaguar Health, Inc. is $262.50, about 34439.5% above the recent price, from 1 analysts.
Is JAGX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Jaguar Health, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.